U.S. markets open in 11 minutes
  • S&P Futures

    3,849.75
    +40.50 (+1.06%)
     
  • Dow Futures

    31,251.00
    +339.00 (+1.10%)
     
  • Nasdaq Futures

    13,061.25
    +150.25 (+1.16%)
     
  • Russell 2000 Futures

    2,239.10
    +39.90 (+1.81%)
     
  • Crude Oil

    61.71
    +0.21 (+0.34%)
     
  • Gold

    1,735.30
    +6.50 (+0.38%)
     
  • Silver

    26.96
    +0.52 (+1.97%)
     
  • EUR/USD

    1.2055
    -0.0032 (-0.27%)
     
  • 10-Yr Bond

    1.4320
    -0.0280 (-1.92%)
     
  • Vix

    24.74
    -4.15 (-14.36%)
     
  • GBP/USD

    1.3944
    +0.0022 (+0.15%)
     
  • USD/JPY

    106.5570
    +0.0550 (+0.05%)
     
  • BTC-USD

    48,060.51
    +3,300.97 (+7.37%)
     
  • CMC Crypto 200

    964.22
    +31.08 (+3.33%)
     
  • FTSE 100

    6,558.83
    +75.40 (+1.16%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Veracyte: Q4 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Veracyte (NASDAQ:VCYT) were unchanged in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were up 6.67% over the past year to ($0.14), which missed the estimate of ($0.11).

Revenue of $34,536,000 up by 16.17% year over year, which beat the estimate of $31,930,000.

Guidance

Veracyte Sees FY21 Sales $190M-$200M Vs. $151.18M Est.

Conference Call Details

Date: Feb 17, 2021

Time: 05:30 PM

View more earnings on VCYT

ET Webcast URL: https://edge.media-server.com/mmc/p/p7geixt9

Price Action

52-week high: $86.03

Company's 52-week low was at $13.90

Price action over last quarter: Up 93.62%

Company Profile

Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis product.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.